Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR1 | P47211 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 9/20 | 0.43 |
| ▸ | ENO1 | P06733 | 1/20 | 0.40 |
| ▸ | MAP3K8 | P41279 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4836878 | 0.93 | GALR1 (0.44) | GALR1EGFRENO1MAP3K8DRD2 | |
| SCHEMBL5032178 | 0.90 | GALR1 (0.49) | GALR1EGFRMAP3K8DRD2 | |
| SCHEMBL4838759 | 0.89 | EGFR (0.45) | GALR1EGFRMAP3K8DRD2 | |
| SCHEMBL4836650 | 0.89 | GALR1 (0.43) | GALR1EGFRENO1DRD2 | |
| SCHEMBL14294122 | 0.89 | GALR1 (0.49) | GALR1ENO1MAP3K8DRD2 | |
| SCHEMBL4832720 | 0.89 | GALR1 (0.59) | GALR1DRD2 | |
| SCHEMBL4829406 | 0.89 | GALR1 (0.59) | GALR1DRD2 | |
| SCHEMBL5036362 | 0.89 | GALR1 (0.59) | GALR1DRD2 | |
| SCHEMBL4832076 | 0.89 | GALR1 (0.59) | GALR1DRD2 | |
| SCHEMBL5553540 | 0.88 | GALR1 (0.46) | GALR1EGFRENO1MAP3K8DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560817-A1 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | Reddy US Therapeutics, Inc. (US) | 2005-08-10 | — | — | EP | claimed |
| WO-2004026844-A9 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | REDDY US THERAPEUTICS INC (US) | 2004-11-11 | — | — | WO | claimed |
| WO-2004026844-A1 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | REDDY US THERAPEUTICS, INC. (US) | 2004-04-01 | — | — | WO | claimed |
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332488-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332488-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332488-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-24 | — | — | US | disclosed |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-24 | — | — | US | disclosed |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-24 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | GALR1 961/4885EGFR 157/4885ENO1 3493/4885 |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | GALR1 961/4885EGFR 157/4885ENO1 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.